Skip to main content

ROKIT Healthcare

ApplicationSeoul, South KoreaFounded 2012· One of 686 Application companies tracked by AMPulse

Develops AI-driven 3D bioprinting platforms for cartilage and skin regeneration, integrating patient-specific imaging, bioink formulation, and in-situ printing for point-of-care tissue repair.

CEO / Founder
Seok-Hwan You
Team Size
51-200
Stage
Public
Total Funding
Publicly Traded
Latest Round
Private Equity
Key Investors
Master Investment Group (MIG); Global large-scale private equity funds and asset management companies

Technology & Products

Key Products

AI Cartilage Regeneration Platform (TCW); Organ Regeneration Platform; EpiTem-2 artificial skin organoid; ROKIT INVIVO bioprinter; Diabetic foot ulcer regeneration patch

Technological Advantage

Proprietary AI-driven bioprinting workflow enables real-time, patient-specific scaffold design and printing path generation, validated in multinational clinical trials; protected by patents (e.g., KR102586031B1, US11612569B2) and trade secrets around bioink formulation and cell processing.

Patent position

ROKIT Healthcare has filed 80 patent families across all years, compared with 52 for CELLINK and 51 for Aspect Biosystems. AMPulse analysis

Filing momentum
2 families filed 2022–2024, 44 in 2019–2021
Filed in
KR 61%US 16%WO 14%CN 9%EP 9%
Named competitors, AM patent families
CELLINK 52Aspect Biosystems 51

80 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.

Differentiation

Value Proposition

Reduces cartilage repair surgery burden and recovery time compared to microfracture/ACI, offering a personalized, single-procedure solution with autologous cell sources (e.g., infrapatellar fat pad) to improve long-term tissue durability and patient outcomes.

How They Differentiate

Focuses on in-situ, point-of-care printing for cartilage and skin regeneration using autologous cells, unlike competitors' off-the-shelf or lab-based bioprinted models; AI integration for real-time personalization and surgical workflow integration.

Market & Competition

Target Customers

Hospitals, orthopedic surgeons, dermatology clinics, and public health systems

Industry Verticals

Medical; Regenerative Medicine; Orthopedics; Dermatology

Competitors

Organovo; CELLINK (BICO); Aspect Biosystems

Growth & Milestones

Growth Metrics

Secured $625M investment from global private equity and asset managers; expanding into public health systems in Italy, Argentina, and the Middle East; multi-center clinical trial enrolling over 100 patients across 13 hospitals.

Major Milestones

KOSDAQ IPO (May 2025); Initiation of global AI cartilage regeneration clinical trial (September 2025); $625M investment from global funds (2025); Entry into Italy's public health system (2026); Partnership with Harvard Medical School for kidney regeneration research

Notable Customers

Public hospital in Milan, Italy; Hospitals in Egypt; Multiple Korean hospitals in clinical trials; Major Korean cosmetics manufacturer (for EpiTem-2)

https://rokithealthcare.com

Recent coverage of ROKIT Healthcare

AM patents

AM-relevant patents linked to this company.

Patents
91
Granted
44
Families
80

Leading domains: process (91), equipment (48), application (35)

Filings by year: 2023: 2 · 2021: 7 · 2020: 21 · 2019: 21 · 2018: 13 · 2017: 3

  1. 동결건조 유리연골 파우더를 이용한 연골 재생용 조성물의 제조방법, 이를 이용하여 제조된 연골 재생용 조성물, 연골 재생용 조성물을 이용한 환자 맞춤형 연골 재생용 스캐폴드의 제조방법 및 환자 맞춤형 연골 재생용 스캐폴드1024344030000 · KR
  2. 3D 프린터(쾌속조형기)용 필라멘트 공급장치인 스프링블록1020130121603 · KR
  3. Three-dimensional bioprinter having multi-syringe output module12427718 · US
  4. BIO PRINTER CAPABLE OF AUTO-LEVELING AND AUTOLEVELING METHOD THEREOF20230173743 · US
  5. 진피 재생 시트용 바이오 잉크 조성물, 이를 이용한 맞춤형 진피 재생 시트의 제조방법, 및 상기 제조방법을 이용하여 제조된 맞춤형 진피 재생 시트1020190174295 · KR

Funding rounds

  • Private Equity$625M2025Lead: Master Investment Group (MIG) · Source: LinkedIn, news articles